Código QR

Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study

Abstract Introduction Tuberculosis is a major public health problem, and its treatment has become challenging due to the emergence of drug-resistant tuberculosis. Since 2022, the World Health Organization has called for the rollout of the 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin...

Descrición completa

Gardado en:
Principais autores: Bisrat Solomon, Abdurehman Seid, Tigle Nadew, Abel Werku, Tigist Mesfin, Altaye Nigussie, Etalemahu Sebro, Robel Gemechu, Eyerusalem Mekonnen, Bontu Abate, Abraham Eshetu, Workye Tigabie, Melaku Solomon, Haimanot Tadesse Mulu
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2026-03-01
Series:BMC Infectious Diseases
Assuntos:
Bedaquiline
Pretomanid
Linezolid
Moxifloxacin
Drug-resistant tuberculosis
Treatment outcome
Acceso en liña:https://doi.org/10.1186/s12879-026-13135-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares